Boots Online Doctor has launched a new medical cannabis service to support patients living with long-term health conditions.
Announced today, the multiple said the SureLeaf service is available for patients aged 25 or over with “eligible chronic pain conditions, generalised anxiety disorder or insomnia”.
Read more: Canadian cannabis company sparks up £2.1m deal in UK
It added that the service offers “another treatment option where conventional treatments have not provided adequate symptom relief, supported by specialist clinical assessment and care”.
Boots also revealed that it is exploring a “collaborative research programme” with the University of Nottingham alongside the service launch to examine patient outcomes, prescribing practices and experience in chronic pain treatment.
Read more: Boots and Uni of Notts partner on research into digital healthcare
The multiple said the SureLeaf service “brings together specialist consultants, multidisciplinary clinical oversight and ongoing patient monitoring through treatment”.
Patients begin their assessment online, and this is then reviewed by the clinical team before progressing to a video consultation with a consultant “in the relevant medical specialty” who is on the General Medical Council Specialist Register.
Read more: Medicinal cannabis in pharmacy: are professional attitudes changing?
Boots said proposed prescriptions “will be independently reviewed by a multidisciplinary clinical team that includes a second, independent consultant, before treatment begins.
“Patients must have previously tried conventional treatments without achieving adequate symptom relief,” it noted.
Read more: Medical cannabis: Is the pharmacy sector ready to roll?
It added that patients will receive “ongoing clinical support and monitoring” once treatment is underway, including an initial review after 28 days followed by reviews “at least every three months”.
And it said questionnaires will be used throughout treatment to assess quality of life, pain, anxiety, sleep and mood to help clinicians monitor the treatment’s effectiveness.
Uni of Nottingham partnership
Alongside the launch of the service, Boots said it is exploring a research programme with the University of Nottingham to “build on the existing real-world evidence and understanding of medical cannabis in chronic pain management”.
The work builds on the existing partnership between the two organisations, and Boots said it aims to “help inform future clinical practice, support responsible service development and contribute to the broader understanding of the role medical cannabis could play”.
Read more: Boots sold for £6.7bn to ex-Selfridges owners
Boots chief healthcare officer Jamie Kerruish said millions live with ongoing pain and that for some, “conventional treatments do not provide adequate symptom relief” which can have a “significant impact on everyday life”.
“Medical cannabis is a specialist area of healthcare and, through SureLeaf, we’re giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care,” he added.
“Strong clinical safeguards”
And Boots Online Doctor medical director Dr David Gwynne stressed that medical cannabis “is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis”.
He added that SureLeaf has been designed with “strong clinical safeguards and specialist oversight at every stage” and said Boots’ priority is to “ensure patients receive responsible, clinically led care”.
Read more: Boots launches new private chest infection service
It comes after Aurora Cannabis paid £2.1m in August for 100% of the shares of Internod Pharma, an importer and wholesaler, and HAP Pharma, a licensed pharmacy, as it looks to service growing demand for medical cannabis from UK patients.
And it follows Boots and the University of Nottingham embarking on a partnership in September to advance research into the future of digital and integrated healthcare.

